{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:32:24Z","timestamp":1774931544082,"version":"3.50.1"},"reference-count":54,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The steroid hormones estrogen and progesterone together regulate the development and maintenance of the female reproductive system. The actions of these two hormones are mediated by their respective nuclear receptors located within overlapping cell populations in target organs. The molecular mechanism of action of these two hormones has been defined to a large extent using estrogen receptor (ER) and progesterone receptor (PR) antagonists. In the case of ER, the available antagonists are highly receptor selective. With respect to PR, however, the available antiprogestins also interact with the receptors for glucocorticoids, mineralocorticoids, and androgens. Whereas these cross-reactivities can usually be managed in studies of female reproductive function, it is the recent demonstration that RU486 is an effective antagonist of the \u03b2-isoform of ER that suggested the need for more selective antiprogestins. In this study, we used cell-based transcriptional assays combined with screens using coactivator peptide analogs to identify two novel classes of antiprogestins that distinguish themselves from the antiprogestin RU486 in the manner they interact with PR. One class exhibits the characteristics of a pure antiprogestin in that its members bind to the receptor and induce a conformational change that prevents the presentation of two potential coactivator binding surfaces on the protein. The second class of compounds distinguish themselves from RU486 in that they are ER\u03b2 sparing. When tested in vivo the ER-sparing antiprogestins were as effective as RU486 in suppressing superovulation. It is anticipated that the availability of these new antiprogestins will advance the studies of PR pharmacology in a manner similar to how the availability of selective ER modulators has helped the study of ER action.<\/jats:p>","DOI":"10.1210\/endo.143.8.8942","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T16:12:27Z","timestamp":1389197547000},"page":"3071-3082","source":"Crossref","is-referenced-by-count":18,"title":["Identification and Characterization of Novel Estrogen Receptor-\u03b2-Sparing Antiprogestins"],"prefix":"10.1210","volume":"143","author":[{"given":"Ganesan","family":"Sathya","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Cancer Biology (G.S., M.S.J., S.C.N., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology (G.S., M.S.J., S.C.N., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology (G.S., M.S.J., S.C.N., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Edgar","family":"Cook","sequence":"additional","affiliation":[{"name":"Chemistry and Life Sciences (C.E.C.), Research Triangle Institute, Research Triangle Park, North Carolina 27709"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology (G.S., M.S.J., S.C.N., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071619594518900_R1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0039-128X(00)00115-X","article-title":"Progesterone receptors in reproduction: functional impact of the A and B isoforms.","volume":"65","author":"Conneely","year":"2000","journal-title":"Steroids"},{"key":"2020071619594518900_R2","first-page":"291","article-title":"The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene.","volume":"54","author":"Giangrande","year":"1999","journal-title":"Recent Prog Horm Res"},{"key":"2020071619594518900_R3","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1128\/MCB.14.12.8356","article-title":"The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells.","volume":"14","author":"Wen","year":"1994","journal-title":"Mol Cell Biol"},{"key":"2020071619594518900_R4","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1073\/pnas.93.16.8739","article-title":"16\u03b1-substituted anologs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity.","volume":"93","author":"Wagner","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619594518900_R5","first-page":"1244","article-title":"Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.","volume":"7","author":"Vegeto","year":"1993","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R6","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/MCB.20.9.3102-3115.2000","article-title":"The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.","volume":"20","author":"Giangrande","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2020071619594518900_R7","first-page":"1167","article-title":"Nuclear receptor coactivators and corepressors.","volume":"10","author":"Horwitz","year":"1996","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0303-7207(98)00145-2","article-title":"Coactivators and corepressors as mediators of nuclear receptor function: an update.","volume":"143","author":"Jenster","year":"1998","journal-title":"Mol Cell Endocrinol"},{"key":"2020071619594518900_R9","first-page":"418","article-title":"Estrogen receptor \u03b2 activates the human retinoic acid receptor \u03b1-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.","volume":"13","author":"Zou","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199308053290607","article-title":"Mifepristone (RU486)\u2014a modulator of progestin and glucocorticoid action.","volume":"329","author":"Spitz","year":"1993","journal-title":"New Engl J Med"},{"key":"2020071619594518900_R11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0959-8049(95)00616-8","article-title":"Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells","volume":"32A","author":"Hackenberg","year":"1996","journal-title":"Eur J Cancer"},{"key":"2020071619594518900_R12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0960-0760(94)90190-2","article-title":"The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity.","volume":"48","author":"McDonnell","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071619594518900_R13","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1016\/S0021-9258(17)32664-9","article-title":"RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism.","volume":"269","author":"McDonnell","year":"1994","journal-title":"J Biol Chem"},{"key":"2020071619594518900_R14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9378(94)90468-5","article-title":"Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus.","volume":"171","author":"Bigsby","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"2020071619594518900_R15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0024-3205(96)00698-4","article-title":"Antiprogestins and iatrogenic glucocorticoid resistance.","volume":"60","author":"Koper","year":"1997","journal-title":"Life Sci"},{"key":"2020071619594518900_R16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.2781282","article-title":"Contragestation and other clinical applications of RU486, an antiprogesterone at the receptor.","volume":"245","author":"Baulieu","year":"1989","journal-title":"Science"},{"key":"2020071619594518900_R17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0960-0760(90)90421-G","article-title":"Treatment of breast cancer with different antiprogestins: preclinical and clinical studies.","volume":"37","author":"Bakker","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071619594518900_R18","first-page":"2","article-title":"Progestational agents in advanced breast cancer: an overview.","volume":"13","author":"Haller","year":"1986","journal-title":"Semin Oncol"},{"key":"2020071619594518900_R19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00165601","article-title":"Steroid hormone receptors in human meningiomas, gliomas and brain metastases.","volume":"1","author":"Poisson","year":"1983","journal-title":"J Neurooncol"},{"key":"2020071619594518900_R20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0015-0282(16)54531-2","article-title":"Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.","volume":"56","author":"Kettel","year":"1991","journal-title":"Fertil Steril"},{"key":"2020071619594518900_R21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"key":"2020071619594518900_R22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(92)90234-4","article-title":"The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor","volume":"69","author":"Vegeto","year":"1992","journal-title":"Cell"},{"issue":"Suppl 1","key":"2020071619594518900_R23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/humrep\/9.suppl_1.12","article-title":"History and perspectives of antiprogestins from the chemist\u2019s point of view","volume":"9","author":"Teutsch","year":"1994","journal-title":"Hum Reprod"},{"issue":"Suppl 1","key":"2020071619594518900_R24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/humrep\/9.suppl_1.32","article-title":"Effects of D-ring substituents on antiprogestational (antagonist) and progestational (agonist) activity of 11 \u03b2-aryl steroids","volume":"9","author":"Cook","year":"1994","journal-title":"Hum Reprod"},{"key":"2020071619594518900_R25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0024-3205(93)90135-P","article-title":"Reversal of activity profile in analogs of the antiprogestin RU 486: effect of a 16 \u03b1-substituent on progestational (agonist) activity.","volume":"52","author":"Cook","year":"1993","journal-title":"Life Sci"},{"key":"2020071619594518900_R26","unstructured":"Cook CE, Kepler JA, Shetty RS, Bartley GS, Lee DY-W October 5, 1999 17\u03b2-Nitro-11\u03b2-arylsteroids and their derivatives having agonist or antagonist hormonal properties. U.S. Patent No. 5,962,444"},{"key":"2020071619594518900_R27","unstructured":"Cook CE, Kepler JA, O\u2019Reilly JM Jan. 9, 2001 17\u03b2-Acyl-17\u03b1-propynyl-11\u03b2-arylsteroids and their derivatives having agonist or antagonist hormonal properties. U.S. Patent No. 6,172,052"},{"key":"2020071619594518900_R28","unstructured":"Cook CE, Shetty RS, Kepler JA, Lee DY-W Mar. 28, 2000 11\u03b2-Ayl-17, 17-spirothiolane-substituted steroids. U.S. Patent No. 6,043,235"},{"key":"2020071619594518900_R29","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1210\/endo.140.3.6581","article-title":"The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins.","volume":"140","author":"Wagner","year":"1999","journal-title":"Endocrinology"},{"key":"2020071619594518900_R30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1021\/ol007067b","article-title":"Effect of a 17\u03b1-(3-hydroxypropyl)-17\u03b2-acetyl substituent pattern on the glucocorticoid and progestin receptor binding of 11\u03b2-arylestra-4, 9-dien-3-ones.","volume":"3","author":"Cook","year":"2001","journal-title":"Org Lett"},{"key":"2020071619594518900_R31","doi-asserted-by":"crossref","first-page":"32889","DOI":"10.1074\/jbc.272.52.32889","article-title":"Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor.","volume":"272","author":"Giangrande","year":"1997","journal-title":"J Biol Chem"},{"key":"2020071619594518900_R32","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/endo.140.12.7179","article-title":"The estrogen receptor \u03b2-isoform (ER\u03b2) of the human estrogen receptor modulates ER\u03b1 transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.","volume":"140","author":"Hall","year":"1999","journal-title":"Endocrinology"},{"key":"2020071619594518900_R33","first-page":"21","article-title":"Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.","volume":"8","author":"Tzukerman","year":"1994","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R34","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1128\/MCB.19.12.8226","article-title":"Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors \u03b1 and \u03b2.","volume":"19","author":"Chang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2020071619594518900_R35","first-page":"2010","article-title":"Development of peptide antagonists that target estrogen receptor \u03b2-coactivator interactions.","volume":"14","author":"Hall","year":"2000","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1126\/science.285.5428.744","article-title":"Peptide antagonists of the human estrogen receptor.","volume":"285","author":"Norris","year":"1999","journal-title":"Science"},{"key":"2020071619594518900_R37","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1074\/jbc.270.39.22777","article-title":"Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers.","volume":"270","author":"Norris","year":"1995","journal-title":"J Biol Chem"},{"key":"2020071619594518900_R38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF02576382","article-title":"Effects of anti-progesterone compound RU486 on ovulation in immature mice treated with PMSG\/hCG.","volume":"194","author":"Kanayama","year":"1994","journal-title":"Res Exp Med"},{"key":"2020071619594518900_R39","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1073\/pnas.96.7.3999","article-title":"Estrogen receptor (ER) modulators each induce distinct conformational changes in ER\u03b1 and ER\u03b2.","volume":"96","author":"Paige","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619594518900_R40","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/1071557600007001S05","article-title":"Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen","volume":"7","author":"McDonnell","year":"2000","journal-title":"J Soc Gynecol Investig"},{"key":"2020071619594518900_R41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0960-0760(00)00109-6","article-title":"Development of peptide antagonists that target estrogen receptor-cofactor interactions.","volume":"74","author":"McDonnell","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071619594518900_R42","first-page":"321","article-title":"Nuclear receptor coregulators: cellular and molecular biology.","volume":"20","author":"McKenna","year":"1999","journal-title":"Endocr Rev"},{"key":"2020071619594518900_R43","first-page":"659","article-title":"Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.","volume":"9","author":"McDonnell","year":"1995","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R44","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/oxfordjournals.humrep.a137519","article-title":"Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice.","volume":"6","author":"Loutradis","year":"1991","journal-title":"Hum Reprod"},{"key":"2020071619594518900_R45","first-page":"1201","article-title":"Hormone induction of progesterone receptor (PR) messenger ribonucleic acid and activation of PR promoter regions in ovarian granulosa cells: evidence for a role of cyclic adenosine 3\u2032, 5\u2032-monophosphate but not estradiol.","volume":"12","author":"Clemens","year":"1998","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R46","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1177\/1071557600007001S09","article-title":"Reproductive functions of the progesterone receptor","volume":"7","author":"Conneely","year":"2000","journal-title":"J Soc Gynecol Investig"},{"key":"2020071619594518900_R47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0303-7207(01)00465-8","article-title":"Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice.","volume":"179","author":"Conneely","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"2020071619594518900_R48","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1126\/science.289.5485.1751","article-title":"Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform.","volume":"289","author":"Mulac-Jericevic","year":"2000","journal-title":"Science"},{"key":"2020071619594518900_R49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0022-4731(86)90087-7","article-title":"Progestin and antiprogestin effects on progesterone receptor transformation.","volume":"24","author":"Spilman","year":"1986","journal-title":"J Steroid Biochem"},{"key":"2020071619594518900_R50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/mend.15.2.0596","article-title":"New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator- induced changes in progesterone receptor induction properties.","volume":"15","author":"Giannoukos","year":"2001","journal-title":"Mol Endocrinol"},{"key":"2020071619594518900_R51","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1074\/jbc.M110090200","article-title":"Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.","volume":"277","author":"Richer","year":"2002","journal-title":"J Biol Chem"},{"key":"2020071619594518900_R52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0039-128X(00)00112-4","article-title":"Progesterone receptor coactivators.","volume":"65","author":"Rowan","year":"2000","journal-title":"Steroids"},{"key":"2020071619594518900_R53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/MCB.18.3.1369","article-title":"The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.","volume":"18","author":"Wagner","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2020071619594518900_R54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/mend.11.6.0004","article-title":"The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7\/SPA and the corepressors N-CoR or SMRT.","volume":"11","author":"Jackson","year":"1997","journal-title":"Mol Endocrinol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/143\/8\/3071\/10370659\/endo3071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/143\/8\/3071\/10370659\/endo3071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T23:27:31Z","timestamp":1647905251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/143\/8\/3071\/2989707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endo.143.8.8942","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,1]]}}}